Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy

NCT00386139 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00386139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00386139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2006
Completion date
July 31, 2007
Enrollment
881 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension